Search results
Showing 91 to 105 of 105 results for rituximab
This guidance has been updated and replaced by NICE technology appraisal guidance 195.
Discontinued [GID-TA10308]
Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]
Discontinued [GID-TA10480]
Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (TA472)
This guidance has been updated and replaced by NICE technology appraisal guidance 629.
The clinical effectiveness and cost effectiveness of rituximab for follicular lymphoma (TA37)
This guidance has been updated and replaced by NICE technology appraisal guidance 137.
Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]
Discontinued [GID-TAG393]
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)
Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.
New agreement means NICE recommends combination treatment for some lymphoma patients
Hundreds of people with a form of blood cancer will benefit from a new treatment following the publication of draft guidance by NICE.
New draft guidance from NICE means thousands of people suffering with severe rheumatoid arthritis will have more medicines to choose from.
Chemotherapy-free treatment option to be offered to patients with England's most common leukaemia
Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.
NICE recommends new 'chemotherapy-free' treatment for lymphoma
A new treatment option for patients with previously treated follicular lymphoma (grade 1 to 3A) has been approved by NICE.
More than 1,000 people each year will benefit from NICE's recommendation
NICE has agreed a managed access agreement, via the Cancer Drugs Fund with manufacturer Kite, so more data can be collected while patients can access the treatment.